There’s a phrase spreading through healthcare right now that should make anyone in obesity medicine pause:

“GLP-1 care.”

It’s everywhere — clinic websites, employer pitch decks, influencer content, and headlines. And on one level, I understand why.

Weight loss remains one of the strongest consumer motivators across healthcare. People will actively seek care, engage longer, and spend more for weight-related outcomes than almost anything else in medicine.

GLP-1 medications have become the cultural symbol of that demand.

So if you’re a healthcare company trying to grow, the incentive is obvious: you sell what people recognize.

And right now, the most recognizable weight-loss “product” in the public imagination is GLP-1 therapy.

But here’s the problem:

At minimum, calling obesity treatment “GLP-1 care” is inaccurate.

At maximum, it’s dangerous.

Not because GLP-1 medications aren’t transformative — they are. But because renaming a medical specialty after a drug class shrinks medicine into marketing.

Obesity medicine has existed long before semaglutide became a household name.

For years, evidence-based treatment has included:

Surgery in particular remains the most effective treatment we’ve ever had at scale for severe obesity, with decades of outcomes data.

GLP-1s didn’t invent obesity care.

They dramatically expanded it.

That’s not the same thing.

The phrase also fails on technical grounds. Many of the most novel obesity medications are not “GLP-1 only” therapies. Modern development is moving toward:

Some emerging therapies even incorporate hormones like glucagon, which is not an incretin hormone — meaning this whole category can’t be reduced to GLP-1 biology.

So what are we actually describing when we say “GLP-1 care”?

A medication? A mechanism? A clinic workflow? A field?

Usually, it’s none of the above.

It’s branding.

Here’s a simple test:

If obesity care can be renamed after a drug class, then every specialty could be renamed, too.

That sounds ridiculous because it is.

Medicine isn’t defined by a drug class. It’s defined by diagnosis, risk stratification, monitoring, longitudinal follow-up, outcomes, etc.

This isn’t semantics. It’s a standards problem.

Language shapes expectations. Expectations shape incentives. Incentives shape what care becomes.

And “GLP-1 care” sends a very specific message: Obesity is managed by getting access to a drug.

That framing creates three major hazards:

1) It reduces care to access

As if obesity is primarily a supply-chain problem.
As if evaluation, education, phenotype selection, and long-term management are optional.

2) It re-trivializes obesity

For decades obesity was reduced to “diet and exercise.” Many of us have worked hard to move beyond that.

But “GLP-1 care” just swaps one trivial narrative for another: It’s not diet. It’s not exercise. It’s a pill (or injection).

That’s not progress.

3) It enables low-standard medicine

A drug-class label creates permission for “strip-down” models:

At that point, “care” becomes a checkout lane.

Obesity deserves better than that.

GLP-1 medications are real medicine. They are profoundly beneficial. They are changing lives.

But they are not obesity care.

Obesity care is bigger than GLP-1s:

That’s what makes it medical care.

Not the drug.

I’m not naïve about why “GLP-1 care” caught on.

Weight loss sells. GLP-1s are culturally dominant. And healthcare companies follow incentives. But we should be honest about what this trend represents:

“GLP-1 care” isn’t a clinical standard. It’s a marketing label.

And if we allow marketing language to replace clinical language, we risk rebuilding obesity medicine into the very thing it’s spent decades trying not to be: a trivialized, transactional version of care.

Obesity is not a diet.
It’s not a workout plan.
And it’s not a drug class.

It’s a disease.

And it deserves comprehensive treatment.